-
Mashup Score: 4FDA Grants Fast Track Status to PT886 for Metastatic Claudin 18.2+ Pancreatic Adenocarcinoma - 1 month(s) ago
PT886 has been granted fast track designation for use as a potential therapeutic option in patients with metastatic claudin 18.2–positive pancreatic adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4FDA Grants Fast Track Status to PT886 for Metastatic Claudin 18.2+ Pancreatic Adenocarcinoma - 1 month(s) ago
PT886 has been granted fast track designation for use as a potential therapeutic option in patients with metastatic claudin 18.2–positive pancreatic adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4FDA Grants Fast Track Status to PT886 for Metastatic Claudin 18.2+ Pancreatic Adenocarcinoma - 2 month(s) ago
PT886 has been granted fast track designation for use as a potential therapeutic option in patients with metastatic claudin 18.2–positive pancreatic adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
FDA Grants Fast Track Status to PT886 for Metastatic Claudin 18.2+ Pancreatic Adenocarcinoma @US_FDA #oncology #pancsm #MedTwitter https://t.co/xASb2WAzFp